SML3834
Vorapaxar
≥98% (HPLC)
别名:
Ethyl [(3aR,4aR,8aR,9aS)-9(S)-[(E)-2-[5-(3-fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1(R)-methyl-3-oxonaphtho[2,3-c]furan-6(R)-yl]carbamate, MK 5348, MK-5348, MK5348, SCH 530348, SCH-530348, SCH530348
登录查看公司和协议定价
所有图片(2)
About This Item
经验公式（希尔记法）:
C29H33FN2O4
CAS号:
分子量:
492.58
MDL编号:
UNSPSC代码:
51111800
UNSPSC代码:
12352200
NACRES:
NA.77
推荐产品
质量水平
方案
≥98% (HPLC)
表单
powder
颜色
white to beige
溶解性
DMSO: 2 mg/mL, clear
储存温度
-10 to -25°C
SMILES字符串
Fc1cc(ccc1)c2cnc(cc2)\C=C\[C@@H]3[C@H]4[C@@H](C[C@H]5[C@H]3CC[C@H](C5)NC(=O)OCC)C(=O)O[C@@H]4C
InChI key
ZBGXUVOIWDMMJE-QHNZEKIYSA-N
生化/生理作用
Orally active, potent and selective thrombin receptor (PAR-1) antagonist with anti-platelet aggregation efficacy in vitro and in vivo.
Vorapaxar (MK-5348; SCH 530348) is an orally active, potent and selective thrombin receptor (PAR-1) antagonist with good selectivity over a panel of GPCRs, ion channels, and receptors, including PAR-2, PAR-3 and PAR-4. Vorapaxar inhibitis thrombin-induced calcium transient and thymidine incorporation in human coronary artery smoothmuscle cells (HCASMC; Ki = 1.1 and 13 nM, respectively), as well as aggregation in human platelet-rich plasma (PRP) induced by 10 nM thrombin or 15 μM haTRAP (IC50 = 47 and 25 nM, respectively), but not 20 μM ADP or 5 μM collagen. Oral administration (0.1 mg/kg to cynomolgus monkeys) prevents haTRAP-induced platelet aggregation ex vivo.
警示用语：
Warning
危险声明
预防措施声明
危险分类
Aquatic Acute 1 - Aquatic Chronic 1
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
Vorapaxar proven to be a promising candidate for pulmonary fibrosis by intervening in the PAR1/JAK2/STAT1/3 signaling pathway-an experimental in vitro and vivo study
European Journal of Pharmacology, 943, 175438-175438 (2023)
Targeting senescent hepatocytes using the thrombomodulin-PAR1 inhibitor vorapaxar ameliorates NAFLD progression
Hepatology (2023)
Samuel Chackalamannil et al.
Journal of medicinal chemistry, 51(11), 3061-3064 (2008-05-02)
The discovery of an exceptionally potent series of thrombin receptor (PAR-1) antagonists based on the natural product himbacine is described. Optimization of this series has led to the discovery of 4 (SCH 530348), a potent, oral antiplatelet agent that is
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门